Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has caught the eye of Citi analyst Geoff Meacham, who has reiterated a Buy rating on the company’s stock. Meacham’s bullish outlook is largely driven ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising new drugs on the horizon. Vertex's price looks quite attractive, relative to ...

Ed is a writer who is passionate about all financial topics. After starting out in the traditional long-form style of online article writing, Ed shifted focus and began contributing snack-sized ...

Abstract: A novel integration scheme is proposed for the accurate numerical evaluation of test (reaction) integrals needed for solving complex direct or inverse electromagnetic problems using surface ...

Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex ...

Google has added new large language models (LLMs) and a new agent builder feature to its AI and machine learning platform Vertex AI at its annual Google Cloud Next conference. The LLM include a public ...

A quadratic function is a polynomial equation of degree two which typically takes the form of y = ax^2 + bx + c, where a, b, and c are constants. The vertex of a quadratic function is the point that ...